DSpace JSPUI
DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets
Learn More
Please use this identifier to cite or link to this item:
http://repo.tma.uz/xmlui/handle/1/2375| Title: | COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY |
| Authors: | Akhmedov Khalmurad Sadullayevich, . Mullokulov Javohir Jamshid ugli,. |
| Keywords: | reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI. |
| Issue Date: | 2025 |
| Citation: | Toshkent |
| Abstract: | Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF -α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce. |
| URI: | http://repo.tma.uz/xmlui/handle/1/2375 |
| Appears in Collections: | Articles |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 21-26 (1).pdf | COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY | 357.45 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.